12 completed. 8 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Vantia Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) Fedovapagon 2 mg, Placebo - Nocturia | Phase 2 / Phase 3 | Completed | Vantia Ltd | 432 | 2016-03-01 | 2018-10-31 |
| A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval Fedovapagon, Moxifloxacin, Placebo (for fedovapagon) - Healthy | Phase 1 | Completed | Vantia Ltd | 43 | 2015-10-01 | 2016-01-06 |
| Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon fedovapagon, Itraconazole, rifampicin - Nocturia | Phase 1 | Completed | Vantia Ltd | 29 | 2015-05-01 | 2015-07-30 |
| Dose Range Finding Study of Fedovapagon in Men With Nocturia fedovapagon 1 mg, fedovapagon 2 mg, fedovapagon 4 mg - Nocturia | Phase 2 | Completed | Vantia Ltd | 358 | 2012-08-01 | 2014-06-20 |
| Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) VA106483 - Nocturia, Benign Prostatic Hypertrophy (BPH) | Phase 1 | Completed | Vantia Ltd | 30 | 2011-03-01 | 2011-08-02 |
| VA106483 Dose Response in Females VA106483, Placebo - Nocturia | Phase 1 | Completed | Vantia Ltd | 21 | 2010-07-01 | 2010-12-01 |
| Efficacy Study of VA106483 in Males With Nocturia. VA106483 - Nocturia | Phase 2 | Completed | Vantia Ltd | 152 | 2009-12-01 | 2014-06-20 |
| VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept VA111913 TS and placebo - Primary Dysmenorrhea | Phase 2 | Completed | Vantia Ltd | 146 | 2009-08-01 | 2014-05-22 |
| VA106483 Dose Response Study in Elderly Males VA106483, Placebo - Nocturia | Phase 1 | Completed | Vantia Ltd | 10 | 2009-06-01 | 2018-05-23 |
| VA106483 and Alpha Blocker Interaction Study in Elderly Males VA106483, Placebo - Nocturia | Phase 1 | Completed | Vantia Ltd | 12 | 2009-04-01 | 2009-11-25 |
| VA111913 TS: First in Human Study VA111913 TS / placebo - Dysmenorrhea | Phase 1 | Completed | Vantia Ltd | 98 | 2008-09-01 | 2009-06-25 |
| Efficacy and Safety of VA106483 in Elderly Males VA106483, Sugar pill - Nocturia | Phase 1 / Phase 2 | Completed | Vantia Ltd | 27 | 2008-08-01 | 2018-10-31 |
Nocturia (10) · Dysmenorrhea (2) · Prostatic Hyperplasia (2) · Hyponatremia (1) · Pain (1)
Sugars (2) · Itraconazole (1) · Moxifloxacin (1) · Rifampin (1)
United States (6) · United Kingdom (4) · Germany (3)
Ralph Schutz (2) · Aris Nikas (1) · Bruce Rankin (1) · Chris Ng (1) · David Beccia (1) · David Bell (1) · Earl Martin (1) · Elizabeth Houser (1) · Evan Goldfischer (1) · Georg Golor, PD Dr med (1) · Georg Golor, PD Dr. med. (1) · H. David Mitcheson (1) · Hilary McElwaine-Johnn, BSc, ASM, MBBS, MRCP, MFPM (1) · Howard Hezmall (1) · Joseph Parkhurst (1)